-
Tytuł:
-
[Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
-
Autorzy:
-
Chen X; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Jiang Y; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhang Y; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Dai W; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Fan R; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Weng X; Cancer Center, Hospital of Integrated Traditional and Western Medicine, Southern Medical University, Guangzhou 510310, China.
He P; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yan F; Cancer Center, Hospital of Integrated Traditional and Western Medicine, Southern Medical University, Guangzhou 510310, China.
Guo Y; Liver Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
-
Źródło:
-
Nan fang yi ke da xue xue bao = Journal of Southern Medical University [Nan Fang Yi Ke Da Xue Xue Bao] 2020 Oct 30; Vol. 40 (10), pp. 1488-1492.
-
Typ publikacji:
-
Journal Article; Randomized Controlled Trial
-
Język:
-
Chinese
-
Imprint Name(s):
-
Original Publication: Guangzhou : Nanfang yi ke da xue xue bao bian ji bu, 2005-
-
MeSH Terms:
-
Carcinoma, Hepatocellular*/drug therapy
Hand-Foot Syndrome*/drug therapy
Hand-Foot Syndrome*/etiology
Hand-Foot Syndrome*/prevention & control
Liver Neoplasms*/drug therapy
Ozone*/therapeutic use
Antineoplastic Agents/*adverse effects
Sorafenib/*adverse effects
Antineoplastic Agents/therapeutic use ; Humans ; Niacinamide/therapeutic use ; Phenylurea Compounds/adverse effects ; Quality of Life ; Sorafenib/therapeutic use
-
References:
-
Am J Infect Control. 2008 Oct;36(8):559-63. (PMID: 18926308)
J Biol Regul Homeost Agents. 2016 Apr-Jun;30(2):621-5. (PMID: 27358159)
Cochrane Database Syst Rev. 2017 Jun 28;6:CD011979. (PMID: 28657134)
Neuroradiol J. 2013 Jun;26(3):347-56. (PMID: 23859294)
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Sep;44(5):473-8. (PMID: 26713519)
J Clin Oncol. 2015 Mar 10;33(8):894-900. (PMID: 25667293)
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Feb 28;43(2):147-151. (PMID: 29559597)
Cardiovasc Hematol Disord Drug Targets. 2015;15(2):127-38. (PMID: 26126818)
Eur J Cancer. 2011 Sep;47(14):2117-27. (PMID: 21664811)
Vopr Onkol. 2015;61(4):571-4. (PMID: 26571824)
Hepatol Int. 2011 Sep;5(3):850-6. (PMID: 21484134)
-
Contributed Indexing:
-
Keywords: advanced hepatocellular carcinoma; hand-foot skin reaction; nursing intervention; ozone oil; sorafenib
-
Substance Nomenclature:
-
0 (Antineoplastic Agents)
0 (Phenylurea Compounds)
25X51I8RD4 (Niacinamide)
66H7ZZK23N (Ozone)
9ZOQ3TZI87 (Sorafenib)
-
Entry Date(s):
-
Date Created: 20201029 Date Completed: 20201102 Latest Revision: 20231104
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7606236
-
DOI:
-
10.12122/j.issn.1673-4254.2020.10.15
-
PMID:
-
33118519
-
Objective: To compare the effects of medical ozone oil and urea ointment for prevention and treatment of hand-foot skin reaction (HFSR) caused by sorafenib in patients with hepatocellular carcinoma (HCC).
Methods: A total of 99 patients diagnosed with advanced HCC according to National Comprehensive Cancer Network (NCCN) who were scheduled to receive sorafenib treatment for the first time were enrolled in this study between April, 2018 and January, 2020. The patients were randomized into medical ozone oil group ( n =49) and urea ointment group (control group, n =49) for treatment with local application of 1 mL medical ozone oil (experimental group) and 10% urea ointment (2 g) on the palm and plantar skin (including the fingers and joints) for 12 weeks (3 times per day) starting at the beginning of sorafenib treatment, respectively. The patients were observed for occurrence of HFSR every 2 weeks for 14 weeks.
Results: Eight patients were excluded for poor compliance or protocol violations, leaving a total of 91 patients for analysis, including 44 in medical ozone oil group and 47 in urea ointment group. Sixteen (36.4%) of patients in ozone oil group developed HFSR, a rate significantly lower than that in urea ointment group (57.4%; P < 0.05). The incidence of grade 2/3 HFSR was also lower in ozone oil group than in urea ointment group (15.9% [7/44] vs 27.7 [13/47]).
Conclusions: Medical ozone oil can significantly reduce the incidence and severity of HFSR to improve the quality of life of HCC patients receiving sorafenib treatment.
